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Background: Inhaled corticosteroid/long-acting β2-agonist combinations (ICS/LABA) have emerged as first line
therapies for chronic obstructive pulmonary disease (COPD) patients with exacerbation history. No randomized clinical
trial has compared exacerbation rates among COPD patients receiving budesonide/formoterol combination (BFC) and
fluticasone/salmeterol combination (FSC) to date, and only limited comparative data are available. This study compared
the real-world effectiveness of approved BFC and FSC treatments among matched cohorts of COPD patients in a large
US managed care setting.
Methods: COPD patients (≥40 years) naive to ICS/LABA who initiated BFC or FSC treatments between 03/01/2009-03/31/2012
were identified in a geographically diverse US managed care database and followed for 12 months; index date
was defined as first prescription fill date. Patients with a cancer diagnosis or chronic (≥180 days) oral corticosteroid (OCS)
use within 12 months prior to index were excluded. Patients were matched 1-to-1 on demographic and pre-initiation
clinical characteristics using propensity scores from a random forest model. The primary efficacy outcome was COPD
exacerbation rate, and secondary efficacy outcomes included exacerbation rates by event type and healthcare resource
utilization. Pneumonia objectives included rates of any diagnosis of pneumonia and pneumonia-related healthcare
resource utilization.
Results: Matching of the identified 3,788 BFC and 6,439 FSC patients resulted in 3,697 patients in each group. Matched
patients were well balanced on age (mean = 64 years), gender (BFC: 52% female; FSC: 54%), prior COPD-related medication
use, healthcare utilization, and comorbid conditions. During follow-up, no significant difference was seen between BFC and
FSC patients for number of COPD-related exacerbations overall (rate ratio [RR] = 1.02, 95% CI = [0.96,1.09], p= 0.56) or by
event type: COPD-related hospitalizations (RR = 0.96), COPD-related ED visits (RR = 1.11), and COPD-related office/outpatient
visits with OCS and/or antibiotic use (RR = 1.01). The proportion of patients diagnosed with pneumonia during the
post-index period was similar for patients in each group (BFC = 17.3%, FSC = 19.0%, odds ratio = 0.92 [0.81,1.04],
p = 0.19), and no difference was detected for pneumonia-related healthcare utilization by place of service.
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Conclusion: This study demonstrated no difference in COPD-related exacerbations or pneumonia events between BFC
and FSC treatment groups for patients new to ICS/LABA treatment in a real-world setting.
Trial registration: ClinicalTrials.gov identifier NCT01921127.
Keywords: Chronic obstructive pulmonary disease (COPD), Inhaled corticosteroid/long-acting β2-agonist combinations
(ICS/LABA), Comparative effectiveness, Controller treatments, Administrative claimsBackground
It is estimated that over 12 million Americans have been
diagnosed with chronic obstructive pulmonary disease
(COPD) [1]. This disease is characterized by poor and
worsening lung function, and is associated with immense
patient and societal burdens [2]. In recognition of this
enormous negative impact, [3,4] the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) identified the
prevention and treatment of exacerbations as leading pri-
orities for the management of COPD [5].
The GOLD 2014 treatment guidelines support the initi-
ation of controller medications for patients with COPD
symptoms and exacerbations [5]. Inhaled corticosteroid/
long-acting β2-agonist combinations (ICS/LABA) are en-
dorsed by the GOLD guidelines as a first-line maintenance
therapy for COPD patients with a history of exacerbations.
Currently, both budesonide/formoterol combination (BFC,
160/4.5 μg) [6] and fluticasone/salmeterol combination
(FSC, 250/50 μg) [7] are indicated for maintenance treat-
ment of airflow obstruction in COPD patients in the
United States (US).
As of now, no randomized clinical studies have com-
pared the treatment effectiveness of FSC versus BFC in
COPD. Limited indirect comparison from RCT is avail-
able; however, given the various definitions of outcomes as
well as variability in disease severities included, compara-
tive effectiveness remains inconclusive [8]. With limited
comparative data available in the US, at least one struc-
tured literature review delineated the distinctive challenges
associated with conducting comparative research into BFC
and FSC therapies for COPD [9,10]. One US-based retro-
spective study, which evaluated sizeable matched cohorts
of COPD patients for 3–6 months, showed that BFC and
FSC treatments had comparable effectiveness with respect
to exacerbation rates and pneumonia events; however,
BFC patients required less rescue medication during the
observation period, which could be an indication that their
symptoms were controlled better [11]. A 12-month, popu-
lation based retrospective study in Canada with matched
COPD cohorts reported that BFC-treated patients were
associated with lower likelihood of emergency department
(ED) visits, inpatient hospitalizations and anticholinergic
medication use versus FSC-treated patients during the fol-
low up period [12]. Similarly, a study that evaluated
matched cohorts queried from primary care records linkedwith Swedish hospital, pharmaceutical and cause of death
registries, reported that long-term BFC treatment was as-
sociated with fewer exacerbations, based on healthcare
utilization measures, compared with FSC therapy [13].
The same Swedish study also found lower rates of pneu-
monia and pneumonia related death in patients treated
with BFC compared to those treated with FSC [14].
The primary objective of this study was to compare the
real-world effectiveness of BFC and FSC treatments
among COPD patients new to ICS/LABA combination
therapy in a population of US managed care enrollees.
One important goal was to help address the evidence gap
of specific relevance to the US, given previous studies
were mostly carried out outside of the US where ICS/
LABA formulation and delivery device variations are dif-
ferent than in the US. This study also compared pneumo-
nia rates for patients initiating either BFC or FSC as
pneumonia is an important safety endpoint among pa-
tients receiving ICS/LABA combination therapy [5,15,16].
Methods
Study design and population
Patients initiating BFC (160/4.5 μg) or FSC (250/50 μg)
between 03/01/2009 and 03/31/2012 were identified in
the HealthCore Integrated Research Environment (HIRE)
and followed for 12 months in this retrospective cohort
study. The index date was defined as the first prescription
fill for BFC or FSC during the intake period. At the time
of this study, the HIRE contained longitudinal claims data
of more than 31 million enrollees from all US census re-
gions. Handling of study materials complied with applic-
able Health Insurance Portability and Accountability Act
(HIPAA) rules. Data were from a limited dataset with de-
identified patient information to preserve patient confi-
dentiality. This non-experimental study was conducted
under the Research Exception provisions of the Privacy
Rule, 45 CFR 164.514(e), and was exempt from Investiga-
tional Review Board (IRB) approval, removing the need
for individual patient authorization.
Inclusion/exclusion criteria
Patients were required to be naïve to ICS/LABA therapy
one year prior to initiating BFC (160/4.5 μg) or FSC (250/
50 μg), where the pharmacy claim date of treatment initi-
ation during the intake period was considered the index
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at the index date, and have at least 12 months of con-
tinuous health plan enrollment, including medical and
pharmacy eligibility, prior to (pre-index period) and fol-
lowing the index date (post-index period). Diagnosis
criteria required for inclusion were at least one in-
patient visit with a primary diagnosis for COPD (ICD-9-
CM diagnosis code 491.xx, 492.xx, or 496.xx), and/or, at
least, one ED visit with a COPD diagnosis (either pri-
mary or secondary), and/or, at least, two other medical
claims with a COPD diagnosis (either primary or sec-
ondary) during the pre-index period. Patients diagnosed
with cancer and those who received ≥180 days of oral
corticosteroid (OCS) therapy during the 12-month pre-Figure 1 Patient selection.index period, and those initiating both study medica-
tions on the same date were excluded from the study.
The number of eligible individuals remaining after each
inclusion criterion is illustrated in Figure 1.
Measurements
Primary outcome
The primary outcome measure was the rate of COPD
exacerbations, calculated as the number of exacerba-
tions during the 12-month post-index period. A COPD
exacerbation was defined as a COPD-related inpatient
hospitalization (inpatient hospitalization with a primary
diagnosis for COPD), and/or a COPD-related ED visit
(an ED visit with a diagnosis for COPD in any position)
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the same day as or within 10 days after an office/out-
patient visit with a diagnosis for COPD. Exacerbations oc-
curring within 14 days of each other were considered a
single event. ED visits resulting in a hospital stay were
counted as an inpatient hospitalization only. Any OCS or
antibiotic prescription fill occurring within 14 days of a
COPD-related ED/inpatient hospitalization was counted
as the ED/hospitalization only. Multiple OCS and/or anti-
biotic fills within 10 days of the same outpatient visit were
only counted as one event.
Sensitivity analysis of primary outcome
Stopping follow-up after switching ICS/LABA therapy
Follow-up was stopped at the date a patient filled an ICS/
LABA that was different from their index medication.
Analysis only included exacerbation events and follow-up
time that occurred prior to the treatment modification
during the 12-month post-index period. Patients who did
not switch ICS/LABA therapy were followed for the entire
12 months.
Using all available follow-up time
Analysis included all available follow-up, for which pa-
tients could be followed beyond 12 months. Follow-up
ended at the end of health plan enrollment or the end of
the study period.
Severe COPD exacerbation events
Analysis only included events associated with COPD-
related inpatient hospitalizations and COPD-related ED
visits.
Secondary outcomes
1. Secondary outcome of exacerbation: time to first
event and exacerbation event types. The time to
the first COPD exacerbation was evaluated to
mitigate the effect of potential switching or
discontinuation of the index ICS/LABA medication
due to treatment failure. The exacerbation rates for
each type of exacerbation type (i.e., COPD-related
inpatient hospitalization, COPD-related ED visit,
and pharmacy claim for OCS and/or antibiotics
with a COPD-related office/outpatient visit) were
analyzed separately.
2. Healthcare utilization (COPD-related and all-
cause) and COPD-related medication use. Included
in this measure were the number of visits by place
of service (inpatient and ICU stays, ED, outpatient
and skilled nursing facility). COPD-related utilization
was defined as the presence of a COPD diagnosis
code (primary diagnosis for inpatient stays or any
diagnosis for other places of service) for that visit.All-cause utilization included healthcare use for any
reason or diagnosis. For COPD-related medication
use, the proportion of patients with at least one
prescription claim for ICS, LABA, long-acting
muscarinic antagonist (LAMA), short acting
β2-agonist (SABA), short-acting muscarinic
antagonist (SAMA), SABA/SAMA combination,
OCS, leukotriene receptor antagonist (LTRA),
roflumilast, theophylline, omalizumab and
antibiotics were identified.
3. Medication adherence. Adherence was measured as
the proportion of days covered (PDC) with the
index medication. PDC was calculated as the days
supply of the index medication during the
post-index period divided by the post-index period
(365 days) [17].
4. Pneumonia events. The diagnosis criteria for
identifying viral, bacterial and aspiration pneumonia
in the administrative claims database was validated
using medical chart review as the referent standard,
and was found to have a positive predictive value of
80% and used for the following analyses.
The outcome of pneumonia (defined as having a
claim with a primary or secondary diagnosis with
the following diagnosis codes: ICD-9-CM 480.xx –
486.xx) was examined in three different ways be-
tween the two cohorts. First, the pneumonia rate
within each cohort was calculated as the proportion
of COPD patients with at least one pneumonia diag-
nosis during the 12 month post-index follow-up.
Second, the time to first pneumonia diagnosis was
analyzed to account for possible differences in tim-
ing of the diagnoses found in the first analysis.
Lastly, pneumonia-related utilization was examined
by each place of service: inpatient, ED, and out-
patient visit.
Data analyses
The retrospective study design allowed for the inclusion
of all patients who met all inclusion/exclusion criteria and
were successfully matched on propensity scores. Based on
an expected exacerbation rate for an ICS/LABA patient of
0.5 per person/year, [12] a rate reduction for a BFC patient
of 20%, alpha level of 0.05, 90% power, and dispersion ef-
fect of 1.2, power calculations resulted in a minimum
necessary sample size of 1,457 matched subjects in each
cohort.
To reduce selection bias and create more comparable
BFC and FSC cohorts, propensity score matching was
used to adjust for confounders measured pre-index
[18-20]. The propensity score for each individual was esti-
mated as the probability of receiving BFC, conditional on
observed baseline characteristics. Random forests were
used to estimate the propensity scores as the probability
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the model was dichotomous, indicating whether a patient
received BFC (1) or FSC (0) therapy. Treatment cohorts
were considered well balanced when the p-value for the
difference between groups was p > 0.05 for each of the
pre-specified variables listed below.
It was specified a priori that study samples would be bal-
anced on age, gender, prior asthma diagnosis, and pre-
index characteristics including COPD-related inpatient
hospitalizations and ED visits, OCS fills, antibiotic fills,
SABA and/or SABA/SAMA fills, LABA fills, and LAMA
fills. Although optional, balance was also achieved for an
additional set of variables, including pre-index exacerba-
tions and comorbid conditions, among others. All statis-
tical models included covariates identified during the
12 month pre-index period as not being balanced after
matching and also the analogous pre-index variable;
for example, when analyzing the number of COPD-
related hospitalizations in the post-index, the model also
controlled for the number of pre-index COPD-related
hospitalizations.
A generalized linear model (GLM) from a negative bino-
mial distribution with a log link function was used to
model the primary outcome (including all sensitivity ana-
lyses) of the number of exacerbations. Covariate adjusted
rates, rate ratios, 95% CIs, and p-values are reported. The
time to first COPD exacerbation and time to first pneumo-
nia diagnosis were analyzed using Cox proportional haz-
ards models. Hazards ratios, 95% CIs, and p-values were
reported alongside Kaplan-Meier curves of the time to first
event. Healthcare utilization was analyzed via negative bi-
nomial regression models for the number of events during
the post-index period, normal linear regression was used
for testing differences in the proportion of days covered
with index medication, ordinal logistic regression was used
to test for differences in the distribution of number of fills
for the index medication (1, 2, 3, or 4 or more), and logistic
regression models were used for the outcomes of at least
one event versus zero events, including the outcome of
pneumonia.
Intent-to-treat populations were used for all analyses.
All outcomes and statistical analysis methods were defined
a priori in the study protocol, and no adjustment was
made for multiple testing. Propensity scores were obtained
using R, [23] while all other analysis was performed using
SAS version 9.4 (Cary, NC).
Results
Cohort matching
A total of 3,788 BFC and 6,439 FSC initiators met all in-
clusion/exclusion criteria prior to matching. Table 1 pre-
sents the balance of demographics and pre-index variables
before and after matching. Following propensity score
matching, a total of 3,697 patients from each cohort werematched. All pre-specified variables were well balanced in
addition to most of the optional variables, including
measures of prior COPD exacerbations and diagnosis of
pneumonia. Variables not pre-specified to be matched, and
remaining imbalanced after the matching algorithm was
complete, were the sum of inpatient hospital stays >5 days
(0 vs. ≥ 1), pre-index LTRA use (0, 1, ≥2), geographic region
(northeast, midwest, south, or west), peripheral vascular
disease/atherosclerosis (yes vs. no), and index prescribing
physician specialty (pulmonologist, internal medicine,
family medicine/general practitioner, cardiologist, allergist/
immunologist, non-physician, or other specialty). These var-
iables were included as covariates in all statistical models.
Demographics and baseline characteristics
Patients were 64 years old on average in each treatment
group and a similar proportion of patients in each cohort
were female (52% of BFC and 54% of FSC initiators)
(Table 1). Additionally, patients had similar rates of previ-
ously diagnosed pneumonia (22% BFC, 23% FSC), asthma
(36% BFC, 35% FSC), and hypertension (69% BFC, 68%
FSC), among other conditions, during the 12-month pre-
index period. Use of prior respiratory medications was
also similar, including fills of OCS, ICS, LAMA, SABA,
and SABA/SAMA combination.
Primary outcome
For the primary outcome, the covariate adjusted rate of
COPD exacerbations was no different for patients initiat-
ing BFC (exacerbation rate = 0.88) or FSC (exacerbation
rate = 0.86) during the 12 months following the initiation
of therapy (rate ratio [RR] = 1.02, 95% CI = [0.96, 1.09],
p = 0.56), as shown in Table 2. There were 48% of BFC
patients and 47% of FSC patients experiencing at least
one COPD exacerbation during the follow-up period.
There was also no difference in the exacerbation rate for
each of the COPD exacerbation event types between the
two groups. Patients in the BFC and FSC cohorts had
similar rates of COPD-related inpatient hospitalizations
(RR = 0.96 [0.79, 1.16], p = 0.66); COPD-related ED visits
(RR = 1.11 [0.97, 1.28], p = 0.13); and OCS/antibiotics
filled within 10 days of a COPD outpatient/office visit
(RR = 1.01 [0.94, 1.09], p = 0.72).
Sensitivity analyses of the primary outcome
As shown in Table 2, the sensitivity analyses were all
consistent with the main analysis, showing no observed
differences in exacerbation rates between the two treat-
ment groups. Stopping follow-up at the presence of an
ICS/LABA switch resulted in exacerbation rates for BFC
and FSC of 0.87, and 0.86, respectively, and a RR of 1.01
[0.95, 1.08], p = 0.68. Using all follow-up time (median
2.1 years and maximum 4.1 years in each group) resulted
in RR = 1.01 [0.95, 1.07], p = 0.77, and limiting to only
Table 1 Propensity score matching results – Required matched variables and exacerbation-related variables
Matching criteria Prior to matching After matching
BFC (n = 3788) FSC (n = 6439) P-value BFC (n = 3697) FSC (n = 3697) P-value
Priority matching
Demographics
Age (mean, SD) 63.7 11.4 65.0 12.0 <0.0001 63.7 11.5 64.0 11.8 0.3139
Female (n, %) 1981 52.3% 3535 54.9% 0.0108 1932 52.3% 1989 53.8% 0.1841
Prior asthma diagnosis (n, %) 1371 36.2% 2078 32.3% <0.0001 1320 35.7% 1280 34.6% 0.3299
COPD severity
Prior COPD inpatient visits (mean, SD) 0.13 0.40 0.15 0.42 0.0252 0.13 0.40 0.14 0.43 0.5613
Prior COPD ED visits (mean, SD) 0.18 0.52 0.18 0.52 0.6520 0.18 0.52 0.19 0.55 0.3530
Prior OCS fills (mean, SD) 1.26 1.74 1.01 1.39 <0.0001 1.22 1.68 1.17 1.54 0.1823
Prior antibiotic fills (mean, SD) 2.74 2.75 2.48 2.61 <0.0001 2.70 2.72 2.70 2.81 0.9441
COPD medications
Prior SABA or SABA/SAMA fills (mean, SD) 2.99 4.45 2.35 3.83 <0.0001 2.89 4.37 2.88 4.41 0.9161
Prior LABA fills (mean, SD) 0.24 1.35 0.11 0.92 <0.0001 0.22 1.29 0.16 1.10 0.1169
Prior LAMA fills (mean, SD) 1.19 2.61 0.98 2.32 <0.0001 1.15 2.55 1.11 2.53 0.5224
Optional matching
Pre-index exacerbations (mean, SD) 1.08 1.25 0.94 1.14 <0.0001 1.07 1.24 1.05 1.23 0.5276
Pre-index exacerbations, ≥1 (n, %) 2337 61.7% 3795 58.9% 0.0060 2267 61.3% 2282 61.7% 0.7199
due to COPD related inpatient visit 426 11.2% 863 13.4% 0.0015 420 11.4% 447 12.1% 0.3291
due to COPD related ED visit 536 14.1% 938 14.6% 0.5615 523 14.1% 553 15.0% 0.3225
due to COPD outpatient/office visit + OCS and/or antibiotics 1797 47.4% 2575 40.0% <0.0001 1732 46.8% 1663 45.0% 0.1073
Pneumonia diagnosis (n, %) 849 22.4% 1567 24.3% 0.0270 823 22.3% 867 23.5% 0.2230
Additional balance was achieved on: index month; prescribing physician a pulmonologist; hospitalization due to cardiovascular disease, hospitalization due to
pneumonia; hospitalization due to asthma; long term oxygen use; comorbid conditions (pulmonary hypertension, chronic respiratory failure, anxiety, depression or
psychotropic drug use, coronary artery disease, left ventricle failure, diabetes, congestive heart failure, hypertension, and stroke); prior medication use categorized
as 0, 1, or 2+ fills for the following classes: OCS, antibiotics, ICS, LAMA, LABA, roflumilast, theophylline, SABA, SAMA, SABA/SAMA combination, omalizumab, and
any cardiovascular related); influenza vaccination; pneumococcal vaccination.
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ing (RR = 1.03 [0.92, 1.16], p = 0.58).
Secondary outcomes
Time to first exacerbation
The analysis of time to first exacerbation was consistent
with that of the exacerbation rates (Hazard ratio [HR] =
1.03 [0.96, 1.10], p = 0.45), in that there were no differ-
ences in risk of COPD exacerbation for patients initiat-
ing BFC compared with those initiating FSC, as shown
in Figure 2.
Medication use and healthcare utilization
Respiratory medication use
Respiratory medication use was similar for both groups.
Approximately a third of patients received LAMA therapy
post-index and nearly half had at least one fill of SABA
medication, with no difference observed between the two
groups. OCS was also received by more than 40% of the
patients, while antibiotics were used by nearly three-
quarters of the patients in each group, as shown in Table 3.Adherence to the index medication
Patients in the BFC cohort filled their index medication
3.8 times on average during the 12-month follow-up
period compared with 4.0 times for FSC patients (mean
difference = −0.20, [−0.34, −0.05], p = 0.01), and 33.9% of
BFC patients filled only their index medication without a
refill in the next 12 months, compared with 32.7% of
FSC patients. This resulted in a low average PDC in both
groups (BFC: mean = 0.33 ± 0.28; FSC: mean = 0.34 ±
0.29), signaling that just one-third of the follow-up
period was covered by supply of either medication on
average.
Healthcare resource utilization
Use of healthcare resources was similar between the two
cohorts during the 12-month post-index period. Just 6.2%
of BFC patients and 6.9% of FSC patients had at least one
COPD-related hospitalization (odds ratio (OR) = 0.91
[0.76, 1.10]), with an average length of stay of 7 days.
COPD-related ED visits were present in 12% of patients
from each group (OR = 1.08 [0.93, 1.24]), and BFC patients
Table 2 COPD exacerbation rates and pneumonia events during the post-index period






Primary Outcome: COPD exacerbation rate 0.88 0.86 1.02 0.96 1.09 0.5637
COPD-related inpatient hospitalization 0.06 0.07 0.96 0.79 1.16 0.6644
COPD-related ED visit 0.14 0.13 1.11 0.97 1.28 0.1304
OCS and/or antibiotics filled within 10 days after a COPD-related outpatient/office
visit
0.67 0.66 1.01 0.94 1.09 0.7153
Sensitivity analysis of primary outcome
Stopping follow-up at ICS/LABA switch2 (within first 12 months of follow-up) 0.87 0.86 1.01 0.95 1.08 0.6787
Using all follow-up3 (≥12 months follow-up) 0.86 0.86 1.01 0.95 1.07 0.7678
Severe COPD exacerbation4 (12 month post-index period) 0.21 0.20 1.03 0.92 1.16 0.5760








Pneumonia events: any event 17.3 19.0 0.92 0.81 1.04 0.1926
Inpatient hospitalization 8.9 10.3 0.87 0.75 1.02 0.0937
ED visit 1.0 1.3 0.80 0.51 1.23 0.3052
Outpatient/office visit 12.0 12.6 0.97 0.84 1.12 0.6404
1: Statistical comparisons are comparing BFC to FSC (reference group). Model covariates include sum of inpatient hospital stays >5 days (yes vs. no), LTRA use (0,
1, 2+), geographic region, peripheral vascular disease / atherosclerosis (yes vs. no), index prescribing physician specialty, and analogous pre-index variable (e.g.,
when analyzing the number of COPD related hospitalizations in the post-index, the model controlled for the number of pre-index COPD related hospitalizations).
2: Patients who filled an ICS/LABA that was different than the index medication during the 12 month post-index period had follow-up stopped on the date of
the switch.
3: Using all follow-up: Patients were followed as long as possible until the end of the continuous health plan enrollment, or the end of the study period.
4: Severe COPD exacerbation includes only events due to COPD related inpatient hospitalization and COPD related ED visit.
CI: confidence interval; ED: emergency department.
Figure 2 Kaplan-Meier curves for time to first COPD exacerbation and pneumonia diagnosis.
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Table 3 COPD medication use – adherence to index medication and prescription fills for other respiratory medication
classes during the post-index period
95% CI
BFC (n = 3,697) FSC (n = 3,697) Estimate1 Lower Upper P-value
Adherence to index medication
Number of fills for index medication (including index fill) (mean, SD) 3.8 3.2 4.0 3.4 −0.20 −0.34 −0.05 0.0071
Patients with only the index fill (n, %) 1,252 33.9% 1208 32.7% 0.95 0.87 1.03 0.2197
Patients with 2 fills (n, %) 563 15.2% 575 15.6%
Patients with 3 fills (n, %) 393 10.6% 398 10.8%
Patients with 4 or more fills (n, %) 1,489 40.3% 1516 41.0%
Proportion of days covered with index medication (mean, SD) 0.33 0.28 0.34 0.29 −0.01 −0.02 0.00 0.0914
COPD respiratory medications (number of patients with at least one fill)
ICS monotherapy use (n, %) 220 6.0% 230 6.2% 0.94 0.78 1.14 0.5250
LAMA monotherapy use (n, %) 1,188 32.1% 1,226 33.2% 0.95 0.86 1.05 0.3232
LABA monotherapy use (n, %) 87 2.4% 78 2.1% 1.12 0.82 1.53 0.4807
Roflumilast (n, %) 23 0.6% 18 0.5% 1.23 0.66 2.29 0.5052
Theophylline use (n, %) 123 3.3% 111 3.0% 1.09 0.84 1.42 0.5120
SABA (n, %) 1,815 49.1% 1,845 49.9% 0.96 0.87 1.05 0.3550
SAMA (n, %) 169 4.6% 178 4.8% 0.95 0.77 1.18 0.6591
SABA/SAMA combination use (n, %) 656 17.7% 646 17.5% 1.03 0.91 1.16 0.6465
OCS monotherapy use (n, %) 1,628 44.0% 1,544 41.8% 1.09 0.99 1.20 0.0674
LTRA monotherapy use (n, %) 498 13.5% 429 11.6% 1.03 0.86 1.25 0.7316
Omalizumab use (n, %) 7 0.2% 5 0.1% 1.30 0.41 4.10 0.6556
Antibiotics use (n, %) 2,686 72.7% 2,667 72.1% 1.02 0.92 1.13 0.7239
1: Covariate adjusted mean differences are used for adherence measures from negative binomial (number of fills) and normal linear regression (proportion
of days covered) models. The covariate adjusted odds ratio from an ordinal logistic regression is reported for the overall distribution of number of index
medication fills (1, 2, 3, or 4+). Covariate adjusted odds ratios from logistic regression models are reported for the proportions of patients with at least one
fill for each medication class. BFC is the reference group for all comparisons. Model covariates include: Sum of inpatient hospital stays >5 days (0 vs. 1),
LTRA use (0, 1, 2+), geographic region, Peripheral vascular disease / atherosclerosis (0 vs. 1), index prescribing physician specialty, and analogous pre-index
variable (for analysis of COPD medication classes only).
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visits on average compared with 10.0 in the FSC group
(adjusted mean difference = −0.26 [−0.63, 0.14]). There
remained no difference between the two groups when
examining all-cause resource utilization (Table 4).Pneumonia analysis
Post-index pneumonia diagnosis and utilization
The proportion of patients diagnosed with pneumonia
during the 12 months following the initiation of therapy
was similar for patients in each group (BFC = 17.3%,
FSC = 19.0%, OR = 0.92 [0.81, 1.04], p = 0.19), as shown
in Table 2. When examined by place of service, there
remained no difference in pneumonia-related events
between groups. Pneumonia-related inpatient hospitaliza-
tions occurred in 8.9% of BFC patients vs. 10.3% of the
FSC group (OR = 0.87 [0.75, 1.02], p = 0.09), pneumonia-
related ED visits were 1.0% vs. 1.3% (OR = 0.80 [0.51,
1.23], p = 0.31), pneumonia-related outpatient/office visits
were 12.0% vs. 12.6% (OR = 0.97 [0.84, 1.12], p = 0.64), andthe time to first pneumonia event was similar (HR = 0.92
[0.83, 1.02], p = 0.12), as shown in Figure 2.
Discussion
In this study of matched cohorts of COPD patients initi-
ating ICS/LABA treatment, no differences were ob-
served in the effectiveness of BFC and FSC for all the
outcome measures evaluated. No difference was ob-
served between the two groups on the primary outcome
measure, COPD exacerbation rates, which was defined
by inpatient hospitalizations, emergency department
visits, and antibiotic/OCS medication use paired with a
COPD outpatient visit. Furthermore, the comparability
of the two treatments remained consistent for all the
sensitivity analyses and secondary measures as well.
Pneumonia, which is an important safety endpoint for
COPD patients initiating ICS/LABA treatment, [5,15,16]
was observed for a similar proportion of patients in the
BFC and FSC cohorts during the follow up period. A
Cochrane systematic review reported that budesonide and
fluticasone, by themselves or with LABA combination
Table 4 Healthcare resource utilization during the 12 month post-index period
Estimate* 95% CI P-value
BFC (N = 3,697) FSC (N = 3,697) Lower Upper
COPD-related healthcare resource utilization
COPD-related inpatient hospitalizations
Number of patients with ≥1 event (n, %) 228 6.2% 255 6.9% 0.91 0.76 1.10 0.3466
Number of events (mean, SD, median)1 1.3 1.1 1.0 1.2 0.7 1.0 0.10 −0.08 0.32 0.3016
Length of stay per patient (mean, SD, median)1 7.0 9.1 4.0 7.2 10.5 4.0 0.04 −0.96 1.21 0.9485
COPD-related ICU stays
Number of patients with ≥1 event (n, %) 24 0.6% 32 0.9% 0.73 0.43 1.25 0.2564
Number of events (mean, SD, median)1 1.3 0.7 1.0 1.1 0.3 1.0 0.13 −0.33 0.85 0.6391
Length of stay per patient (mean, SD, median)1 1.8 2.0 1.0 2.7 8.5 1.0 0.16 −0.66 1.73 0.7661
COPD-related ED visits
Number of patients with ≥1 event (n, %) 453 12.3% 438 11.8% 1.08 0.93 1.24 0.3123
Number of events (mean, SD, median)1 1.4 0.9 1.0 1.4 0.9 1.0 0.02 −0.11 0.18 0.7462
COPD-related outpatient/office visits
Number of patients with ≥1 event (n, %) 3,047 82.4% 3,072 83.1% 0.93 0.82 1.05 0.2500
Number of events (mean, SD, median)1 9.6 11.9 5.0 10.0 12.8 5.0 −0.26 −0.63 0.14 0.1966
All-cause healthcare resource utilization
All-cause inpatient hospitalizations
Number of patients with ≥1 event (n, %) 1,131 30.6% 1,178 31.9% 0.98 0.89 1.09 0.7422
Number of events (mean, SD, median)1 1.9 1.5 1.0 2.0 1.7 1.0 0.04 −0.06 0.14 0.4678
Length of stay per patient (mean, SD, median)1 9.3 14.6 5.0 11.2 17.2 5.0 −0.10 −0.44 0.25 0.5528
All-cause ICU stays
Number of patients with ≥1 event (n, %) 220 6.0% 241 6.5% 0.95 0.78 1.15 0.5631
Number of events (mean, SD, median)1 1.2 0.6 1.0 1.3 0.7 1.0 0.00 −0.18 0.21 0.9906
Length of stay per patient (mean, SD, median)1 2.0 5.5 1.0 1.9 4.2 1.0 0.00 −0.22 0.26 0.9910
All-cause ED visits
Number of patients with ≥1 event (n, %) 1,012 27.4% 1,003 27.1% 1.05 0.94 1.16 0.4070
Number of events (mean, SD, median)1 1.6 1.4 1.0 1.7 1.7 1.0 0.02 −0.08 0.14 0.6778
All-cause outpatient/office visits
Number of patients with ≥1 event (n, %) 3,679 99.5% 3,669 99.2% 1.59 0.88 2.88 0.1274
Number of events (mean, SD, median)1 33.1 30.7 25.0 34.9 32.3 27.0 0.03 −0.44 0.52 0.8925
*: Odds ratio from logistic regression is used for dichotomous variables (0 vs.1); Odds ratio from ordinal logistic regression is used for ordinal variables (0 vs. 1
vs. 2+); mean difference from negative binomial models is used for count variables. Statistical comparisons are comparing BFC to FSC (reference group); i.e.,
Mean diff = mean (BFC)-mean(FSC) and OR = Odds(BFC)/Odds(FSC). Model covariates include: Sum of inpatient hospital stays >5 days (0 vs. 1), LTRA use (0, 1, 2
+), geographic region, Peripheral vascular disease / atherosclerosis (0 vs. 1), index prescribing physician specialty, and analogous pre-index variable.
1: Including only patients with at least one event; length of stay defined as the number of days from admission to discharge. Same date admission and discharge
were counted as one.
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events but were not significantly associated with mor-
tality. The review noted that comparisons of the treat-
ments showed no significant difference in serious
pneumonia, deaths or adverse events [15]. However,
prior research has suggested a lower rate of pneumonia
outcomes in those treated with BFC rather than FSC,
[14] and a study of ICS therapies showed decreased
rates of pneumonia in budesonide patients indirectly
compared with those treated with fluticasone, [24] andsimilar results were reported in a meta-analysis of ran-
domized clinical trials [25]. The lack of difference in
our study may be due to low adherence rates when
compared with the series of clinical trials, [25] which
showed relatively low rates of discontinuation, and the
Swedish observational study by Janson et al. [14] which
analyzed only patients who were currently treated with
drug. There may have also been differences in disease
severity between the study populations, but we did not
have access to clinical measurements to appropriately
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selecting eligible patients for the current study was
similar to that in the Janson study, in that the only re-
quirement was a diagnosis code for COPD prior to ini-
tiation of therapy and there was no requirement of
having a prior exacerbation or any other clinical event.
Although the baseline periods are different between
our study (1 year) and the Swedish study (2 years),
comparable proportions of patents with a prior COPD
exacerbation (77% in Janson et al. vs. 62% in our study)
and a prior pneumonia diagnosis (25% vs. 23%) were
observed.
While the findings of this study indicate similar ef-
fectiveness of BFC and FSC with respect to COPD
measures, this is in contrast to findings from a number
of earlier studies that examined these two drugs. A
Canadian study that followed a smaller matched sam-
ple (N = 2262) for a similar duration as our study, re-
ported that COPD patients receiving BFC were less
likely to be hospitalized or use ED services and re-
quired less anticholinergic medications than patients
on FSC. The authors cautioned, however, that the ob-
servational nature of their study precluded any conclu-
sions that medication alone was responsible for the
observed effects [12].
A study conducted with data from the Swedish na-
tional registry system (21,361 medical records) over a
much longer follow-up period (11 years) reported
lower rates across all exacerbation outcomes among
patients receiving BFC relative to FSC for moderate-
to-severe COPD [13]. In contrast to our study, the
Swedish registry study had a longer treatment duration
(3.5 years on average) and only assessed outcomes for
patients while they were on treatment. The present
analysis was performed using an intent-to-treat design
where outcomes may be influenced by poor adherence
to treatment. Patients who remain on treatment for
longer periods of time might experience different out-
comes from what was observed in the present study.
This could also indicate that one year of observation
following treatment initiation may not be enough time
to assess effectiveness between these two medications,
and that relative effects between BFC and FSC manifest
much later in treatment.
A study conducted by Roberts et al. in the US found
that BFC and FSC had comparable effectiveness in
terms of COPD exacerbation rates and pneumonia
events, although the BFC patients required less rescue
medication during the observation period. Similar to
the current study, this study had a relatively short
follow-up period, with only up to 6 months post treat-
ment initiation which may not have been long enough
to observe differences in COPD exacerbations and
pneumonia events [11].In general, the exacerbation rates found in the present
study are smaller than some other studies, likely due to
the fact that COPD severity is milder in this population
that did not require prior exacerbations for inclusion,
and did not have spirometry data to confirm diagnoses.
It should also be noted that there are device differences
for BFC in various countries (e.g., Turbuhaler in Sweden
versus pressurized metered-dose inhaler in the US);
however we do not believe that device type would be a
primary reason for observed differences between the
studies.
Despite differences between the findings of our study
and those from earlier research, the findings of this study
will be a valuable addition to this area because it drew
from treatment data linked to a sizeable, commercially-
insured population across the entire country facilitating
access to a large number of patients with geographic di-
versity. The retrospective nature of the study enabled
both looking backwards and forwards from a given
point in time (the index date) without having to actively
follow patients over time as is required in a prospective
study.
More than 30% of patients in each group had a diag-
nosis of asthma during the pre-index period. Such pa-
tients are traditionally excluded from COPD studies,
including clinical trials. By including potential asthma-
COPD overlap patients in this study the findings have
much greater generalizability to the COPD population.
The study used a robust study design in which pa-
tients were propensity-score matched (resulting in well
balanced treatment groups across pre-index characteris-
tics) and followed for an entire year. The Random For-
est method utilized in the propensity score algorithm
has been shown to be more effective in balancing treat-
ment cohorts with less bias compared with traditional
logistic regression techniques [21]. Another important
strength was that pneumonia diagnoses were validated
via medical record abstraction, which found an 80%
positive predictive value of pneumonia diagnoses in the
claims data when compared with medical records.
Limitations
The results of this study must be viewed against several
limitations, although none are expected to have differ-
entially affected the treatment groups. The results are
only generalizable to a commercially insured US popu-
lation, and are based on data which are primarily col-
lected for billing and reimbursement purpose, and may
be subject to potential coding errors and inconsisten-
cies. This study was conducted within a real-world set-
ting and patients were not required to continuously take
the index medication during follow-up. Individuals filled
their index medication an average of approximately 4
times, which resulted in them having medication for
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study compares patients initiating BFC therapy versus FSC
therapy, but not necessarily patients who were actively tak-
ing medication. In fact, 34% of BFC patients and 33% of
FSC patients only had a single fill of the index medication.
Because of this, and because patients were taking other re-
spiratory medications during the follow-up period (for ex-
ample more than 30% of patients were also taking LAMA
therapy), we cannot attribute outcomes solely to the initi-
ated ICS/LABA therapy.
There was a lack of detailed clinical information, includ-
ing smoking status and pulmonary function assessment, to
adjust for COPD disease severity and activity because such
information is absent from the primary data source, ad-
ministrative claims. However, the study matched on prior
COPD exacerbations which are the best predictor of future
exacerbations [5]. The follow-up time in this study might
have been insufficient to evaluate a less frequent event (i.e.,
pneumonia). Exacerbation rates could be underestimated
as we did not capture events through OCS or antibiotic
prescription dispensing via telephone (in the absence of an
office visit) and most inpatient administered medications
are not present in the claims data. Off-label use of the
study medications (e.g., FSC 500/50 μg) was not captured,
and there might be an ICS dose relationship to the in-
creased risk of pneumonia which could not be examined
here. Lastly, this was a non-randomized study, which may
detect associations but causation cannot be inferred.Conclusion
No differences were found between patients initiating BFC
or FSC in a real-world setting, in terms of rates of exacer-
bations, measured by COPD-related inpatient hospitaliza-
tions, emergency department visits, and outpatient visits
with antibiotic/OCS medication use. This result was con-
sistent across all sensitivity analyses and secondary end-
points. Pneumonia rates during the first year of initiating
the therapy were also similar between the two groups, with
similar rates of healthcare resource utilization and respira-
tory medication use.
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